Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia

Brett Schroeder, Constance M. Yuan, Hao-Wei Wang, Chirayu Mohindroo, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Catherine Feurtado, Lacey James-Echenique, Katherine R Calvo, Irina Maric, Robert J. Kreitman

Blood blood.2025031243.

https://doi.org/10.1182/blood.2025031243

Published: 2025

Includes: Supplemental data

Journal Articles

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova, Hao-Wei Wang, Alexandra E. Kovach, Constance M. Yuan, Dana Delgado Colon, Loïc Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Assim Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H. Chang, Raymund S. Cuevo, Barbara De Moerloose, David S. Dickens, Ulrich Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R. Fitzjohn, Zhubin Gahvari, Stephan A. Grupp, Rui Rochelle He, Cynthia Harrison, Christopher B. Hergott, Emily M. Hsieh, Annette S. Kim, Dennis J. Kuo, Daniel P. Larson, Benjamin J. Lee, Thibaut Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L. Pacenta, Jing Pan, Marlie Provost, Latika Puri, Sunil S. Raikar, Armando Martinez, Isabella Bristol, Kyle Murphy, Lauren Reiman, Michele Redell, Kelly Reed, Gabrielle Roth-Guepin, Jeremy Rubinstein, Süreyya Savaşan, Kristian Schafernak, Alexandra Stevens, Aimee Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Liping Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R. Rheingold, Kara L. Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam J. Lamble, Nirali N. Shah

Blood (2025) 146 (4): 437–455.

https://doi.org/10.1182/blood.2024026655

Published: 2025

Includes: Supplemental data

Journal Articles

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood blood.2024026919.

https://doi.org/10.1182/blood.2024026919

Published: 2025

Includes: Supplemental data

Journal Articles

Non-V600E BRAF mutations and treatment for hairy cell leukemia

Evgeny Arons, Chin-Hsien Tai, Joshi Suraj, Yuelin Liu, Chi-Ping Day, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Isaac Shpilman, Cristopher C. Oakes, Seema Bhat, Michael Grever, Daniel Jones, Kerry Rogers, Hao-Wei Wang, Constance M. Yuan, Cenk Sahinalp, Robert J. Kreitman

Blood (2025) 145 (17): 1957–1961.

https://doi.org/10.1182/blood.2024026894

Published: 2025

Includes: Supplemental data

Journal Articles

RNA-Lnp-Mediated CAR-T Cell Manufacturing: A Paradigm Shift in Precision Immunotherapy

Xiulian Sun, Sheng Zhao, Wei Wang

Blood (2024) 144 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2024-204121

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Lijun Mu, Hai Lin, Hebing Zhou, Hong-xia Shi, Jinghua Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2024-201204

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Blood (2024) 144 (Supplement 1): 7463.

https://doi.org/10.1182/blood-2024-194638

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Real-World Effectiveness and Safety Analysis of Carfilzomib-Pomalidomide- Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Study from Eastern Shandong of China

Huishou Fan, Rongxia Wei, Xiangyan Feng, Xin Zhang, Tianlan Li, Lu Liu, Hui Wang, Lingjie Sun, Xue Shi, Hongguo Zhao, Zhao Li, Jingying Cui, Xianqi Feng, Junqing Xu, Junjie Ma, Lugui Qiu, Wei Wang

Blood (2024) 144 (Supplement 1): 7032.

https://doi.org/10.1182/blood-2024-207159

Published: 2024

Journal Articles

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Weiwei Zhao, Juan Liu, Liyan Chen, Lianjie Wang, Yanming Xue, Yaoyao Tian, Yao Liu, Xiushuai Dong, Yuying Chang, Xi Chen, Liqian Yu, Xiaomin Zhang, Yinglan Jin, Yan Song, Biqing Han, Dandan Yao, Wei Wang

Blood (2024) 144 (Supplement 1): 7024.

https://doi.org/10.1182/blood-2024-204383

Published: 2024

Journal Articles

Trends and Attributable Risk Factors of the Global Burden of Lymphoid Malignancies over the Past Fifteen Years

Hongyan Tong, Wei Lang, Wei Wang, Yingwan Luo, Wenli Yang, Li Ye, Wenbin Yang, Hua Huang, Xinghua Zhen

Blood (2024) 144 (Supplement 1): 7579.

https://doi.org/10.1182/blood-2024-206675

Published: 2024

Journal Articles

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

Fujing Zhang, Wei Wang, Hua Wang, Wei Wang, Aijun Liu, Weiwei Tian, Xiaoqi Qin, Zhongjun Xia, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6985.

https://doi.org/10.1182/blood-2024-209342

Published: 2024

Journal Articles

A Machine Learning Readmission Risk Prediction Model for Classical and Malignant Hematologic Disease

Angela Bailey, Wei Wang, Clarence Shannon, IV, Jared Huling, Christopher Tignanelli

Blood (2024) 144 (Supplement 1): 7536.

https://doi.org/10.1182/blood-2024-211172

Published: 2024

Journal Articles

The Landscape of Clonal Characteristics and Evolution with Clinical Implications in B Cell Non-Hodgkin's Lymphoma

Shixin Lu, Zhouyi Xu, Zhaoxun Zhang, Yun Gu, Shunjin Zhang, Chuanshu Gao, Liang Zhang, Wei Wang, Zefeng Lu, Jinghua Wu, Zizhao Gao, Zhe Wang, Xiao Liu

Blood (2024) 144 (Supplement 1): 6223.

https://doi.org/10.1182/blood-2024-206471

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2024-209462

Published: 2024

Journal Articles

Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

Blood (2024) 144 (Supplement 1): 4794.

https://doi.org/10.1182/blood-2024-206406

Published: 2024

Journal Articles

CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China

Chao Chen, Jingjing Yin, Wei Wang, Danqing Zhao, Chong Wei, Cong-Wei Jia, Wei Zhang, Jian Li, Daobin Zhou, Yan Zhang

Blood (2024) 144 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2024-202966

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Non-V600E BRAF mutations and treatment for hairy cell leukemia

RNA-Lnp-Mediated CAR-T Cell Manufacturing: A Paradigm Shift in Precision Immunotherapy

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Real-World Effectiveness and Safety Analysis of Carfilzomib-Pomalidomide- Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Study from Eastern Shandong of China

Efficacy and Safety of Carfilzomib-Based Regiments for the Treatment of Relapsed or Refractory Multiple Myeloma: Single-Center Real-Word Data

Trends and Attributable Risk Factors of the Global Burden of Lymphoid Malignancies over the Past Fifteen Years

Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China

A Machine Learning Readmission Risk Prediction Model for Classical and Malignant Hematologic Disease

The Landscape of Clonal Characteristics and Evolution with Clinical Implications in B Cell Non-Hodgkin's Lymphoma

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China

Email alerts

ASH Publications

American Society of Hematology